A Phase 2B Double-Blind Randomized Placebo-Controlled Multicenter Dose-Ranging Study to Evaluate the Efficacy and Safety Profile of PF-06700841 in Participants with Active Systemic Lupus Erythematosus (SLE)

Brief description of study

The purpose of this study is to compare the effects of the study drug PF 06700841 tablets, at different doses with a placebo to find out which is better for Lupus. The study drug, PF 06700841, is an investigational drug because it is not approved for use in United States. The placebo looks like the study drug but does not contain any active ingredients. Researchers will compare the results of taking the placebo to the results of taking the study drug to see if there are any differences.


Clinical Study Identifier: s19-00644
ClinicalTrials.gov Identifier: NCT03845517
Principal Investigator: David H. Goddard.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.